title: Hypereosinophilic Syndrome as a Rare Cause of Reversible Biventricular Heart Failure.
abstract: Hypereosinophilic syndrome is a rare entity that can develop secondary to overproduction of eosinophilopoietic cytokines or as idiopathic disease. Cardiac involvement, which occurs often, is divided into 3 stages, the latter of which is nonreversible and leads to severe heart failure. Early detection and treatment of the syndrome is essential. For this reason, genetic testing for the FIP1L1-PDGFRA fusion gene has recently been added to the diagnostic algorithm. Patients with this mutation are at increased risk for the development of cardiac involvement and typically respond to treatment with the tyrosine kinase inhibitor imatinib mesylate.
authors.affiliation: Department of Cardiology, Laikon General Hospital, Athens, Greece. Electronic address: bonou.maria@yahoo.com.
authors.forename: Maria
authors.initials: M
authors.lastname: Bonou
authors.affiliation: Department of Cardiology, Laikon General Hospital, Athens, Greece.
authors.forename: Chris J
authors.initials: CJ
authors.lastname: Kapelios
authors.affiliation: Department of Cardiology, Laikon General Hospital, Athens, Greece.
authors.forename: George
authors.initials: G
authors.lastname: Benetos
authors.affiliation: Department of Cardiology, Laikon General Hospital, Athens, Greece.
authors.forename: Ioannis
authors.initials: I
authors.lastname: Moyssakis
authors.affiliation: First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
authors.forename: Nefeli
authors.initials: N
authors.lastname: Giannakopoulou
authors.affiliation: First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Diamantopoulos
authors.affiliation: Department of Pathology, National and Kapodistrian University of Athens, Athens, Greece.
authors.forename: Penelope
authors.initials: P
authors.lastname: Korkolopoulou
authors.affiliation: First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
authors.forename: Eleni
authors.initials: E
authors.lastname: Variami
authors.affiliation: Department of Cardiology, Laikon General Hospital, Athens, Greece.
authors.forename: John
authors.initials: J
authors.lastname: Barbetseas
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001856:Bone Marrow Examination / Q000379:methods; D004452:Echocardiography / Q000379:methods; D006333:Heart Failure / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D000068877:Imatinib Mesylate / Q000008:administration & dosage*; D008297:Male; D009154:Mutation; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D011241:Prednisone / Q000008:administration & dosage*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics; D013927:Thrombosis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D016896:Treatment Outcome; D014859:Warfarin / Q000008:administration & dosage*; D039221:mRNA Cleavage and Polyadenylation Factors / Q000235:genetics
chemical_list: D000925:Anticoagulants; D000970:Antineoplastic Agents; D015514:Oncogene Proteins, Fusion; D039221:mRNA Cleavage and Polyadenylation Factors; D014859:Warfarin; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha; D011241:Prednisone